title: Hormone replacement therapy and lipoprotein changes during early menopause.
abstract: The relationship of postmenopausal hormone replacement therapy to lipoproteins was assessed in a cohort of 211 healthy premenopausal women followed during the menopausal transition. Both estrogen and estrogen-progestogen users had minimal increases in low-density lipoprotein (LDL) cholesterol levels, whereas non-users had significant increases in LDL cholesterol over time. Estrogen users had a nonsignificant increase in high-density lipoprotein (HDL) cholesterol, estrogen-progestogen users maintained premenopausal HDL cholesterol levels, and non-users had decreases in HDL cholesterol. Both estrogen and estrogen-progestogen users had increases in apolipoprotein AI, apolipoprotein AII, and triglycerides relative to the changes observed among the menopausal non-users. In summary, estrogen, whether administered with or without medroxyprogesterone acetate, could provide cardiovascular benefits to postmenopausal women by protecting against the atherogenic changes in LDL and HDL cholesterol observed among the non-users. With the exception of the hormone-related increases in triglycerides, the results are consistent with a beneficial effect of hormone replacement therapy on coronary heart disease risk.
authors.affiliation: Department of Epidemiology, University of Pittsburgh, Pennsylvania.
authors.forename: G M
authors.initials: GM
authors.lastname: Egeland
authors.forename: L H
authors.initials: LH
authors.lastname: Kuller
authors.forename: K A
authors.initials: KA
authors.lastname: Matthews
authors.forename: S F
authors.initials: SF
authors.lastname: Kelsey
authors.forename: J
authors.initials: J
authors.lastname: Cauley
authors.forename: D
authors.initials: D
authors.lastname: Guzick
mesh_terms: D000328:Adult; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015331:Cohort Studies; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008593:Menopause / Q000097:blood*; D008875:Middle Aged; D015999:Multivariate Analysis; D012307:Risk Factors; D013997:Time Factors
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004966:Estrogens, Conjugated (USP); D008074:Lipoproteins; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone